Análisis Argos
NBIX
NBIXCara
Neurocrine Biosciences, Inc. · Healthcare
US$ 174.26
precio al 2026-07-04
Valor justo Argos*
US$ 127–140
vs. su valor justo
24% por encima
Score Argos
58/100
LA RESPUESTA
El mercado le pide crezca 24.7% al año — más de lo que ha demostrado (16.3%). Estás pagando un futuro que todavía no probó: el margen de error es mínimo.
Recompensas
✓Las ganancias crecieron 40% el último año.
✓Tiene más caja que deuda: balance fuerte.
Riesgos
!El precio pide más crecimiento del que la empresa ha demostrado.
VALOR2/6FUTURO6/6PASADO4/6SALUD6/6DIVIDENDO2/6
El Iris de calidad
VALOR2/6FUTURO6/6PASADO4/6SALUD6/6DIVIDENDO2/6
ValorCerca de su valor justo
FuturoIngresos creciendo con fuerza
PasadoFundamentales sólidos y sostenidos
SaludBalance fuerte, deuda controlada
DividendoRetorno al accionista moderado
Score Argos58de 100Cara
Ingresos▲21%
US$ 2.9 B
Margen operativo▼11%
21.6%
Flujo de caja libre▲34%
US$ 0.8 B
Deuda neta
US$ -0.3 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 17.5B
P/E36.6x
EV/EBITDA26.5x
FCF yield4.3%
ROIC14.2%
Margen operativo21.6%
Crecim. ingresos+21.4%/año
Piotroski F6/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

seekingalpha.com · 2 jul
Neurocrine Biosciences: Why I Am Upholding A Buy Rating After M&A Deal For Soleno
Neurocrine Biosciences, Inc. remains a Buy, driven by robust growth from Ingrezza, Crenessity, and the recent Vykat acquisition. Q1 2026 revenues rose 44% year-on-year to $811m, with Ingrezza and Crenessity annualizing at blockbuster levels and Vykat showing rapid ramp-up. NBIX stock valuation reflects high-growth expectations; forward P/S ~5.1x and P/E ~30x, justified by an expanding commercial portfolio and pipeline catalysts.
prnewswire.com · 1 jul
Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia
SAN DIEGO, July 1, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont in children aged 3 months to under 4 years with classic congenital adrenal hyperplasia (CAH). Crinecerfont, marketed as CRENESSITY®, is approved in the United States as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients 4 years of age and older with classic CAH.
zacks.com · 1 jul
Neurocrine Biosciences (NBIX) Is Up 6.46% in One Week: What You Should Know
Does Neurocrine Biosciences (NBIX) have what it takes to be a top stock pick for momentum investors? Let's find out.
zacks.com · 1 jul
5 Relative Price Strength Stocks to Buy for the Second Half
NBIX, MYRG, XYZ, DK and DY show strong relative price strength, upbeat estimate revisions and solid fundamentals heading into the second half.
zacks.com · 24 jun
Is Neurocrine (NBIX) a Solid Growth Stock? 3 Reasons to Think "Yes"
Neurocrine (NBIX) could produce exceptional returns because of its solid growth attributes.
zacks.com · 24 jun
Best Momentum Stocks to Buy for June 24th
NBIX, ILPT and CASY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 24th, 2026.
zacks.com · 24 jun
New Strong Buy Stocks for June 24th
BY, NVGS, NBIX, TFII and BG have been added to the Zacks Rank #1 (Strong Buy) List on June 24th, 2026.
zacks.com · 24 jun
Best Value Stocks to Buy for June 24th
NVGS, BY and NBIX made it to the Zacks Rank #1 (Strong Buy) value stocks list on June 24th, 2026.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.